Nature Communications (Apr 2020)
Exploiting evolutionary steering to induce collateral drug sensitivity in cancer
- Ahmet Acar,
- Daniel Nichol,
- Javier Fernandez-Mateos,
- George D. Cresswell,
- Iros Barozzi,
- Sung Pil Hong,
- Nicholas Trahearn,
- Inmaculada Spiteri,
- Mark Stubbs,
- Rosemary Burke,
- Adam Stewart,
- Giulio Caravagna,
- Benjamin Werner,
- Georgios Vlachogiannis,
- Carlo C. Maley,
- Luca Magnani,
- Nicola Valeri,
- Udai Banerji,
- Andrea Sottoriva
Affiliations
- Ahmet Acar
- Evolutionary Genomics and Modelling Lab, Centre for Evolution and Cancer, The Institute of Cancer Research
- Daniel Nichol
- Evolutionary Genomics and Modelling Lab, Centre for Evolution and Cancer, The Institute of Cancer Research
- Javier Fernandez-Mateos
- Evolutionary Genomics and Modelling Lab, Centre for Evolution and Cancer, The Institute of Cancer Research
- George D. Cresswell
- Evolutionary Genomics and Modelling Lab, Centre for Evolution and Cancer, The Institute of Cancer Research
- Iros Barozzi
- Department of Surgery and Cancer, Imperial College London
- Sung Pil Hong
- Department of Surgery and Cancer, Imperial College London
- Nicholas Trahearn
- Evolutionary Genomics and Modelling Lab, Centre for Evolution and Cancer, The Institute of Cancer Research
- Inmaculada Spiteri
- Evolutionary Genomics and Modelling Lab, Centre for Evolution and Cancer, The Institute of Cancer Research
- Mark Stubbs
- CRUK Cancer Therapeutics Unit, The Institute of Cancer Research
- Rosemary Burke
- CRUK Cancer Therapeutics Unit, The Institute of Cancer Research
- Adam Stewart
- Clinical Pharmacology—Adaptive Therapy Group, Division of Cancer Therapeutics and Clinical Studies, The Institute of Cancer Research
- Giulio Caravagna
- Evolutionary Genomics and Modelling Lab, Centre for Evolution and Cancer, The Institute of Cancer Research
- Benjamin Werner
- Evolutionary Genomics and Modelling Lab, Centre for Evolution and Cancer, The Institute of Cancer Research
- Georgios Vlachogiannis
- Gastrointestinal Cancer Biology and Genomics Team, Centre for Evolution and Cancer, The Institute of Cancer Research
- Carlo C. Maley
- Arizona Cancer Evolution Center, Biodesign Institute, Arizona State University
- Luca Magnani
- Department of Surgery and Cancer, Imperial College London
- Nicola Valeri
- Gastrointestinal Cancer Biology and Genomics Team, Centre for Evolution and Cancer, The Institute of Cancer Research
- Udai Banerji
- CRUK Cancer Therapeutics Unit, The Institute of Cancer Research
- Andrea Sottoriva
- Evolutionary Genomics and Modelling Lab, Centre for Evolution and Cancer, The Institute of Cancer Research
- DOI
- https://doi.org/10.1038/s41467-020-15596-z
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 14
Abstract
Evolutionary steering uses therapies to control tumour evolution by exploiting trade-offs. Here, using a barcoding approach applied to large cell populations, the authors explore evolutionary steering in lung cancer cells treated with EGFR inhibitors.
